SGLT2 inhibitor
Idiopathic Pulmonary Fibrosis
Clinical trials
1
Developer
The University of Hong Kong
Overview
SGLT2 inhibitor is an agent tracked by PF-Atlas in the context of idiopathic pulmonary fibrosis. It appears in 1 tracked IPF clinical trial.
SGLT2 inhibitor clinical trials
Explore related
Medical disclaimer. This page summarizes research about SGLT2 inhibitor for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.